KDR and non-small cell lung carcinoma: Similarly, Aokage et al. conducted a phase II trial on neoadjuvant treatment with pembrolizumab plus ramucirumab, a VEGFR-2 antibody antagonist, for PD-L1 positive NSCLC, stage IB-IIIA [82].